APA (7th ed.) Citation

Chen, Z., Cheng, S., Xu, A., Han, C., Jia, X., & Liu, M. Syringin as a novel therapeutic agent for renal cell carcinoma by targeting EGFR/PI3K/Akt pathway and enhancing sunitinib efficacy. Elsevier.

Chicago Style (17th ed.) Citation

Chen, Zixuan, Sheng Cheng, An Xu, Chengtao Han, Xing Jia, and Min Liu. Syringin as a Novel Therapeutic Agent for Renal Cell Carcinoma by Targeting EGFR/PI3K/Akt Pathway and Enhancing Sunitinib Efficacy. Elsevier.

MLA (9th ed.) Citation

Chen, Zixuan, et al. Syringin as a Novel Therapeutic Agent for Renal Cell Carcinoma by Targeting EGFR/PI3K/Akt Pathway and Enhancing Sunitinib Efficacy. Elsevier.